CN113662911A - High-adhesion pain-relieving hydrogel patch and preparation method thereof - Google Patents
High-adhesion pain-relieving hydrogel patch and preparation method thereof Download PDFInfo
- Publication number
- CN113662911A CN113662911A CN202110883065.5A CN202110883065A CN113662911A CN 113662911 A CN113662911 A CN 113662911A CN 202110883065 A CN202110883065 A CN 202110883065A CN 113662911 A CN113662911 A CN 113662911A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- analgesic
- preparation
- polymerization
- adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The embodiment of the disclosure provides a high-adhesion analgesic hydrogel patch and a preparation method thereof, and the preparation method comprises the steps of mixing an acrylamide aqueous solution, dopamine, an additive and a cross-linking agent; uniformly mixing, adding an initiator at a preset temperature, and obtaining polyacrylamide hydrogel after a preset time; the value range of the preset temperature is 30-70 ℃; the value range of the preset time is 0.5-3 hours; and loading analgesic drug molecules to the polyacrylamide hydrogel to obtain the high-adhesion analgesic hydrogel patch. The hydrogel patch has natural adhesiveness and antibacterial property, the loaded analgesic drug endows the hydrogel patch with excellent analgesic performance, the preparation method is simple, and the applicability is wide.
Description
Technical Field
The invention relates to the technical field of hydrogel, in particular to a high-adhesion pain-relieving hydrogel patch and a preparation method thereof.
Background
Pain is one of the most common clinical symptoms, and the pain patients in China, including cancer pain, degenerative diseases of bone joints and neuromuscular diseases, are more and more, and according to the survey and statistics of the Chinese medical treatment and disease control committee: in 2000 samples, the pain incidence was 12%, with 59.1% of patients in the 30-40 year old population; patients account for 81% of the population 50-60 years of age, while pain is seen to be as high as 82% in those over 60 years of age. If the population of the urban area is 100 million, the disease incidence rate is 12 percent as an example, the sick people are 12 million, if the population is 100 million in the aging dense city, the population is 50-60 years old, and 40 million is assumed, the disease incidence rate is 81-82 percent according to the survey statistics of the medical disease control committee, the number of the sick people is 32.4 million, the sick people can see the disease repeatedly, and each patient can see the disease repeatedly, and the condition that 200 yuan per person also has 6480 million market capacity is assumed. If a local city with 100 million people, more than 10 secondary hospitals, share 1200 million each year.
While many types of pharmaceutical formulations are currently delivered to the affected area by the adhesive effect of compress, the adhesive effect merely brings the drug close to the target area, but the drug does not fully conform to the area, thereby limiting the bioavailability of the immobilized drug. On the other hand, the adhesive effect of such applications often relies on a surface adhesive coating, and such a hermetic coating mostly causes side effects on the affected area.
Therefore, there is a need to develop a new patch to improve the adhesion and safety of the patch and to improve the bioavailability of the immobilized drug.
Disclosure of Invention
The present disclosure is directed to solving at least one of the technical problems of the related art or related art.
To this end, in a first aspect of the present disclosure, there is provided a method for preparing a high-adhesion analgesic hydrogel patch, comprising:
mixing an aqueous acrylamide solution, dopamine, an additive and a crosslinking agent;
uniformly mixing, adding an initiator at a preset temperature, and obtaining polyacrylamide hydrogel after a preset time; the value range of the preset temperature is 30-70 ℃; the value range of the preset time is 0.5-3 hours;
and loading analgesic drug molecules to the polyacrylamide hydrogel to obtain the high-adhesion analgesic hydrogel patch.
Further, the analgesic drug molecule comprises;
lidocaine, bupivacaine and/or morphine.
Further, it is characterized in that,
the hydrogel material is a cross-linked polymer of acrylamide and dopamine;
the polydopamine molecules are formed by oxidative self-polymerization of dopamine molecules.
Further, it is characterized in that,
the cross-linking agent of the cross-linked polymer is N, N-methylene bisacrylamide, divinylbenzene or diisocyanate.
Further, it is characterized in that,
the additive of the cross-linked polymer is silk fibroin, clay and/or chitosan.
Further, it is characterized in that,
the initiator of the cross-linked polymer is ammonium peroxide or potassium peroxide.
Further, it is characterized in that,
the polymerization method of the crosslinked polymer is thermal polymerization.
Further, it is characterized in that,
the polymerization temperature of the crosslinked polymer is from 30 ℃ to 70 ℃.
Further, it is characterized in that,
the polymerization time of the crosslinked polymer is 0.5 to 3 hours.
In a second aspect of the present disclosure, a high-adhesion analgesic hydrogel patch is provided, which is prepared according to the above-mentioned preparation method.
The main material components of the invention have the following functions and effects:
lidocaine: the hydrochloride is white crystalline powder, is easy to dissolve in water, has strong and durable local anesthesia effect and good surface penetrating power, and can be injected and used for surface anesthesia; is generally used for treating arrhythmia and the like, is a current medicament for preventing and treating acute myocardial infarction and various heart diseases complicated by rapid ventricular arrhythmia, and is a first-choice medicament for ventricular premature beat, ventricular tachycardia and ventricular tremor of the acute myocardial infarction;
bupivacaine: the long-acting amide local anesthetic has strong anesthetic effect and quick response. The anesthetic is used for nerve block anesthesia, such as brachial plexus block, cervical plexus block, sciatic nerve block and the like, intraspinal anesthesia, such as epidural anesthesia, subarachnoid block and combined anesthesia of lumbar vertebra, and can also be used for local anesthesia or local infiltration anesthesia;
morphine: can be used for relieving moderate and severe pain. E.g., for cancer analgesia, postoperative analgesia, etc.;
acrylamide: used as a raw material for organic synthesis and a raw material for a polymer material. The polymer is usually soluble in water, and has good effect on flocculation of protein and starch in water. The flocculant has excellent performances of flocculation, thickening, shearing resistance, resistance reduction, dispersibility and the like;
dopamine: nerve conduction material to help cells deliver pulsed chemicals.
Has the advantages that: the hydrogel patch disclosed by the invention can solve the problem of poor skin bonding performance of the currently sold medical patch, has an obvious analgesic effect in certain specific cases, and additionally has an antibacterial and anti-inflammatory therapeutic effect on the hydrogel patch, so that the bioavailability of a fixed medicament is improved while the poor adhesion and safety of the existing patch are improved.
Drawings
The above and other features, advantages and aspects of various embodiments of the present disclosure will become more apparent by referring to the following detailed description when taken in conjunction with the accompanying drawings. In the drawings, like or similar reference characters designate like or similar elements, and wherein:
FIG. 1 is a machine drawing of a high adhesion analgesic hydrogel patch according to one embodiment of the present application.
Detailed Description
The principles and features of this invention are described below in conjunction with embodiments, which are included to explain the invention and not to limit the scope of the invention.
In addition, the term "and/or" herein is only one kind of association relationship describing an associated object, and means that there may be three kinds of relationships, for example, a and/or B, which may mean: a exists alone, A and B exist simultaneously, and B exists alone. In addition, the character "/" herein generally indicates that the former and latter related objects are in an "or" relationship.
As shown in fig. 1, the polydopamine molecules are formed by oxidative self-polymerization of dopamine molecules during the preparation of the hydrogel film.
Wherein the analgesic is lidocaine, bupivacaine or morphine;
the cross-linking agent of the cross-linked polymer is N, N-methylene bisacrylamide, divinyl benzene or diisocyanate;
the additive of the cross-linked polymer is silk fibroin, clay or chitosan;
the initiator of the cross-linked polymer is ammonium peroxide or potassium peroxide;
the polymerization method of the crosslinked polymer may be thermal polymerization;
the polymerization temperature of the crosslinked polymer is 30 ℃ to 70 ℃; preferably 50 ℃;
the polymerization time of the crosslinked polymer is 0.5 to 3 hours; preferably 2 hours.
In the present disclosure, the polyacrylamide is prepared by a peroxide initiator initiated free radical polymerization. In order to release the loaded drug molecules smoothly, the drug molecule loading adopts a drug molecule solution dropping method, and the hydrogel patch with the pain relieving function is obtained after the dropped drug smoothly permeates into the hydrogel body. In order to improve the loading rate of the drug molecules, the drug molecule loading can adopt a molecular imprinting technology, i.e. imprinting molecules are added in the hydrogel polymerization process (the molecules do not influence the free radical polymerization of the hydrogel). The prepared hydrogel patch can be temporarily stored by preservative film. The hydrogel patch may be applied directly to the skin or a breathable compress may be applied to the patch.
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Preparation of lidocaine-loaded polydopamine-doped polyacrylamide hydrogel
1) Preparation of polydopamine-doped polyacrylamide hydrogel: uniformly mixing 2 ml of acrylamide, 0.05 g of N, N-methylene bisacrylamide and 0.05 g of ammonium peroxide in ice water, transferring the mixed prepolymer into a water bath kettle at 37 ℃, and obtaining polydopamine-doped polyacrylamide hydrogel with high adhesion performance after 2 hours;
2) loading of lidocaine drug molecules: and (3) washing the obtained hydrogel for 3 times by using water, transferring 0.1 ml of 20 mass percent lidocaine hydrochloride solution by using a liquid transfer gun, uniformly dripping the lidocaine hydrochloride solution on the surface of the polyacrylamide hydrogel, and cooling to a ventilation position until the liquid gradually permeates into the gel to obtain the lidocaine-loaded polydopamine-doped polyacrylamide hydrogel.
Example 2
Preparation of bupivacaine-loaded silk fibroin-added polydopamine-doped polyacrylamide hydrogel
1) Pre-polymerization of silk fibroin and dopamine: 5 ml of 10% aqueous fibroin solution was mixed with 10 mg of dopamine hydrochloride, and the mixture was stirred magnetically at 50rmp for 24 hours until the solution became dark brown.
2) Preparation of the silk fibroin-added polydopamine-doped polyacrylamide hydrogel: uniformly mixing 1 ml of the pre-polymerization solution with 2 ml of acrylamide, 0.05 g of N, N-methylene bisacrylamide and 0.05 g of ammonium peroxide in ice water, transferring the mixed prepolymer into a water bath kettle at 37 ℃, and obtaining the polydopamine-doped polyacrylamide hydrogel with high adhesion performance after 2 hours;
3) loading of bupivacaine drug molecules: and (3) washing the obtained hydrogel for 3 times by using water, transferring 0.1 ml of 20 mass percent bupivacaine hydrochloride solution by using a liquid transfer gun, uniformly dripping the solution on the surface of the polyacrylamide hydrogel, and cooling to a ventilation position until the liquid gradually permeates into the gel to obtain the bupivacaine-loaded polydopamine-doped polyacrylamide hydrogel.
Example 3
Preparation of poly-dopamine-doped polyacrylamide hydrogel added with morphine-loaded clay molecules
1) Pre-polymerization of clay molecules and dopamine: 5 ml of 10% clay molecule water solution is mixed with 10 mg of dopamine hydrochloride, and the mixture is mixed for 24 hours under magnetic stirring at the rotating speed of 50rmp until the solution turns from clear to dark brown.
2) Preparing a polydopamine-doped polyacrylamide hydrogel added with clay molecules: uniformly mixing 1 ml of the pre-polymerization solution with 2 ml of acrylamide, 0.05 ml of N, N-methylene bisacrylamide and 0.05 g of ammonium peroxide in ice water, transferring the mixed prepolymer into a water bath kettle at 50 ℃, and obtaining the polydopamine-doped polyacrylamide hydrogel with high adhesion performance after 1 hour;
3) loading of morphine drug molecules: and (3) washing the obtained hydrogel with water for 3 times to obtain the hydrogel with the morphine molecular imprinting, transferring 0.1 ml of morphine hydrochloride solution with the mass fraction of 20% by using a liquid transfer gun, uniformly and dropwise coating the morphine hydrochloride solution on the surface of the polyacrylamide hydrogel, and cooling to a ventilation position until the liquid gradually permeates into the gel to obtain the morphine-loaded polydopamine-doped polyacrylamide hydrogel.
Claims (10)
1. A preparation method of a high-adhesion pain-relieving hydrogel patch is characterized by comprising the following steps:
mixing an aqueous acrylamide solution, dopamine, an additive and a crosslinking agent;
uniformly mixing, adding an initiator at a preset temperature, and obtaining polyacrylamide hydrogel after a preset time; the value range of the preset temperature is 30-70 ℃; the value range of the preset time is 0.5-3 hours;
and loading analgesic drug molecules to the polyacrylamide hydrogel to obtain the high-adhesion analgesic hydrogel patch.
2. The method of claim 1, wherein the analgesic drug molecule comprises;
lidocaine, bupivacaine and/or morphine.
3. The method of claim 2,
the hydrogel material is a cross-linked polymer of acrylamide and dopamine;
the polydopamine molecules are formed by oxidative self-polymerization of dopamine molecules.
4. The method of claim 3,
the cross-linking agent of the cross-linked polymer is N, N-methylene bisacrylamide, divinylbenzene or diisocyanate.
5. The method of claim 4,
the additive of the cross-linked polymer is silk fibroin, clay and/or chitosan.
6. The method of claim 5,
the initiator of the cross-linked polymer is ammonium peroxide or potassium peroxide.
7. The method of claim 6,
the polymerization method of the crosslinked polymer is thermal polymerization.
8. The method of claim 7,
the polymerization temperature of the crosslinked polymer is from 30 ℃ to 70 ℃.
9. The method of claim 8,
the polymerization time of the crosslinked polymer is 0.5 to 3 hours.
10. A high-adhesion analgesic hydrogel patch, characterized in that it is prepared by the preparation method according to any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110883065.5A CN113662911A (en) | 2021-08-02 | 2021-08-02 | High-adhesion pain-relieving hydrogel patch and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110883065.5A CN113662911A (en) | 2021-08-02 | 2021-08-02 | High-adhesion pain-relieving hydrogel patch and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113662911A true CN113662911A (en) | 2021-11-19 |
Family
ID=78541157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110883065.5A Pending CN113662911A (en) | 2021-08-02 | 2021-08-02 | High-adhesion pain-relieving hydrogel patch and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113662911A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432275A (en) * | 2022-01-20 | 2022-05-06 | 南京医科大学第二附属医院 | Preparation method of high-adhesion analgesic hydrogel microneedle patch and microneedle patch |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035167A1 (en) * | 1998-11-25 | 2002-03-21 | Allyson Beuhler | Polyacrylamide hydrogels and hydrogel arrays made from polyacrylamide reactive prepolymers |
| CN108264611A (en) * | 2018-01-30 | 2018-07-10 | 江汉大学 | A kind of preparation method from the superpower hydrogel of adherency |
| CN109260509A (en) * | 2018-11-27 | 2019-01-25 | 浙江海洋大学 | A kind of self assembly contact-type anti-bacterial hydrogel dressing and preparation method thereof based on poly-dopamine and chitosan oligosaccharide |
| CN110551299A (en) * | 2019-10-23 | 2019-12-10 | 广东工业大学 | Self-adhesive polyacrylamide composite hydrogel and preparation method and application thereof |
| CN111500004A (en) * | 2020-04-28 | 2020-08-07 | 大连理工大学 | High-strength self-healing hydrogel based on dopamine and preparation method thereof |
| CN111675789A (en) * | 2020-06-15 | 2020-09-18 | 暨南大学 | Polydopamine-heparin/quaternary ammonium salt/polyacrylamide hydrogel and preparation |
| CN112442195A (en) * | 2019-09-05 | 2021-03-05 | 中国科学院宁波材料技术与工程研究所 | Preparation method and application of nano hydrogel |
-
2021
- 2021-08-02 CN CN202110883065.5A patent/CN113662911A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020035167A1 (en) * | 1998-11-25 | 2002-03-21 | Allyson Beuhler | Polyacrylamide hydrogels and hydrogel arrays made from polyacrylamide reactive prepolymers |
| CN108264611A (en) * | 2018-01-30 | 2018-07-10 | 江汉大学 | A kind of preparation method from the superpower hydrogel of adherency |
| CN109260509A (en) * | 2018-11-27 | 2019-01-25 | 浙江海洋大学 | A kind of self assembly contact-type anti-bacterial hydrogel dressing and preparation method thereof based on poly-dopamine and chitosan oligosaccharide |
| CN112442195A (en) * | 2019-09-05 | 2021-03-05 | 中国科学院宁波材料技术与工程研究所 | Preparation method and application of nano hydrogel |
| CN110551299A (en) * | 2019-10-23 | 2019-12-10 | 广东工业大学 | Self-adhesive polyacrylamide composite hydrogel and preparation method and application thereof |
| CN111500004A (en) * | 2020-04-28 | 2020-08-07 | 大连理工大学 | High-strength self-healing hydrogel based on dopamine and preparation method thereof |
| CN111675789A (en) * | 2020-06-15 | 2020-09-18 | 暨南大学 | Polydopamine-heparin/quaternary ammonium salt/polyacrylamide hydrogel and preparation |
Non-Patent Citations (1)
| Title |
|---|
| 薛巍 等: "《生物医用水凝胶》", vol. 1, 暨南大学出版社, pages: 35 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432275A (en) * | 2022-01-20 | 2022-05-06 | 南京医科大学第二附属医院 | Preparation method of high-adhesion analgesic hydrogel microneedle patch and microneedle patch |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3115625B2 (en) | Topical patch containing lidocaine | |
| CA2569072C (en) | Preparation for localized delivery of therapeutic agent | |
| US6347246B1 (en) | Electrotransport adhesive for iontophoresis device | |
| US20040077991A1 (en) | Iontophoretic delivery patch | |
| KR101203768B1 (en) | Low-frequency stimulation electrode conductive hydrogel patch containing ingredients for alleviating pain and inflammation | |
| US20200179314A1 (en) | Lidocaine Patch and Methods of Use Thereof | |
| CN113662911A (en) | High-adhesion pain-relieving hydrogel patch and preparation method thereof | |
| US6953590B1 (en) | Tape material for transcutaneous absorption | |
| WO2020211762A1 (en) | Lipid pharmaceutical preparation and application thereof | |
| JP2000219623A (en) | Tacky gel composition for iontophoresis and device therefor | |
| Ignelzi et al. | A statistical analysis of percutaneous radiofrequency lesions in the treatment of chronic low back pain and sciatica | |
| CN108578540A (en) | A kind of biologic formulation and preparation method thereof for inhibiting scar and promoting wound healing | |
| Hariz et al. | Thalamic stereotaxis for chronic pain: ablative lesion or stimulation? | |
| CN101057959B (en) | Medicinal composition for treating derangement syndrome of small joints in lumbar spine and waist support | |
| CN114432275A (en) | Preparation method of high-adhesion analgesic hydrogel microneedle patch and microneedle patch | |
| CN100488572C (en) | Sulfadiazine salt high-molecular hydrogel dressing and its preparation method | |
| KR20010080563A (en) | Pressure-sensitive adhesive gel composition for iontophoresis and apparatus therefor | |
| JPH05255119A (en) | Drug carrier | |
| Seifert et al. | Local Anesthetics | |
| CN107198776A (en) | Pharmaceutical preparation for promoting body-surface rauma healing and preparation method thereof | |
| RU2818449C1 (en) | Method of regional anesthesia/analgesia in operations on thyroid and parathyroid glands | |
| JPH09286891A (en) | Sticky gel base and sticky composition | |
| US10464887B2 (en) | Method for producing active ingredient for rivastigmine free base transdermal patch and rivastigmine free base transdermal patch comprising the same | |
| KR102200787B1 (en) | Elastic bandage with wettability using nanocellulose | |
| Sageer et al. | ESRA19-0299 Bilateral infraclavicular and anterior suprascapular nerve blocks for operative fixation of bilateral proximal humerus fractures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |